Work Here?
Overview
Precede Biosciences uses a blood test to read epigenomic signals in plasma. It analyzes circulating chromatin and the DNA methylome from a single milliliter of blood to determine the activation status of about 20,000 gene promoters and 1 million gene enhancers, providing a transcriptional biology view of disease. The platform supports drug development through Research Use Only partnerships with biopharmaceutical companies and academia, and aims to develop clinical blood-based tests that can replace invasive tissue biopsies for guiding precision medicines in cancers such as breast, lung, prostate, and colorectal. Unlike purely genomic tests, this approach focuses on epigenomic regulation to reveal disease biology, treatment response, and resistance. The company seeks to help identify therapeutic targets and mechanisms driving outcomes, with a goal of accelerating biomarker discovery and enabling non-invasive, dynamic insights into cancer biology.
About Precede Biosciences
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$140.5M
Headquarters
Boston, Massachusetts
Founded
2021
Your Connections
People at Precede Biosciences who can refer or advise you
Simplify's Take
What believers are saying
- Precede Bio Insight opens pharma collaborations for longitudinal biomarker studies.
- AACR 2026 data support breast, prostate, and lung cancer use cases.
- Target and pathway readouts fit radioligands, ADCs, and endocrine therapies.
What critics are saying
- RUO status delays reimbursement and clinical revenue.
- Liquid biopsy must match tissue biomarkers, or confidence collapses.
- Large diagnostics incumbents can outspend and out-distribute Precede quickly.
What makes Precede Biosciences unique
- Genome-wide epigenomic liquid biopsy from 1 mL plasma, not single-gene testing.
- Infers promoter, enhancer, expression, pathway activity, and cell-state biology.
- Built from Dana-Farber research and supports RUO plus clinical products.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$140.5M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
Hybrid Work Options
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Stock Options
Company Equity
Professional Development Budget
Conference Attendance Budget
Training Programs
Tuition Reimbursement
Mentorship Program
Phone/Internet Stipend
Home Office Stipend
Family Planning Benefits
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -3%2 year growth
↓ -3%Precede Biosciences, a precision diagnostics company focused on enabling next-generation precision medicines, has secured $83.5 million in total financing, comprising $63.5 million in Series B equity and a $20 million non-dilutive credit facility. The Boston-based company's platform supports development and clinical use of cancer therapies where target expression and pathway activity serve as defining biomarkers, including drug-, radio-, and immune-conjugates. The funding will scale operations to meet growing demand from developers of these precision medicines. New investors include Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital and Alexandria Venture Investments, alongside existing backers. The expanded investor base brings expertise in diagnostics commercialisation and health system adoption.
Precede Biosciences unveils groundbreaking clinical data for its pioneering Liquid Biopsy platform at ESMO 2023 and simultaneously publishes in Nature Medicine.
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.Teva is focused on ensuring the safety of its employees and doesn’t expect the war to have a “meaningful impact” on its business. AFP via Getty ImagesM ore than 2,250 people have been killed since the Palestinian militant group Hamas launched an assault on Israel over the weekend. Tel Aviv-based Teva, one of the largest generic drugmakers in the world, told Forbes that the $14.9 billion company (2022 sales) has been focused on ensuring the safety of its employees and doesn’t expect the war to have a “meaningful impact” on its business. Israel accounts for around 2% of Teva’s global revenues and 8% of total global production.“We are deeply saddened by the unprecedented, horrific, and brutal attacks on Israeli civilians, including women and children,” spokesperson Kelley Dougherty said in a statement. “As an Israeli company we condemn this appalling assault and Teva stands with Israel in this time of great loss and challenge.” Dougherty said the company has backup manufacturing locations for key products
Unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activation of individual genes and...
Precede Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Precede Biosciences
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$140.5M
Headquarters
Boston, Massachusetts
Founded
2021
Precede Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today